Please enter exact key words
A New Generation Bombesin Receptor Antagonists

for the Treatment of Solid Tumors

Home / Available Projects / A New Generation Bombesin Receptor Antagonists
Drug Name GPCR-targeted Project 008

A new generation antagonist bombesin analogue is being developed for the treatment of solid tumors. The drug candidate binds selectively and with high affinity to the GRP receptors expressed by several types of tumors and can be developed as radio-labeled therapeutic or diagnostic agent.

Target Gastrin releasing peptide receptor (GRPR)
Drug Modality Small molecule
Indication Solid tumors
Product Category New Molecular Entity
Mechanism of Action GRPR antagonist
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.